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Abstract  21 
Background: Hemoglobin A1c (HbA1c), provides a reliable measure of glycemic 22 
control over 2 to 3 months in human diabetes mellitus (DM). In dogs, formation of 23 
HbA1c has been demonstrated, but there are no validated commercial assays.  24 
Objective: To validate a commercially available automated immunoturbidimetric 25 
assay for canine HbA1c and determine a reference interval in a hospital population 26 
of various ages and breeds.  27 
Methods: The specificity of the assay was assessed by inducing glycosylation in 28 
vitro using isolated canine hemoglobin. Repeatability was assessed by measuring 29 
canine samples 5 times in succession, long term inter-assay imprecision by 30 
measuring   supplied control materials, stability using samples stored at 4˚C over 5 31 
days and -20˚C over 8 weeks, linearity by mixing samples of known HbA1c in 32 
differing proportions, and the effect of anticoagulants by taking paired samples. A 33 
reference interval was determined using EDTA-anticoagulated blood samples from 34 
60 non-diabetic hospitalised animals of various ages and breeds. HbA1c was also 35 
measured in dogs with DM (n=10).  36 
Results: HbA1c increased proportionally with glucose concentration in vitro. The 37 
mean repeatability was 4.1% (range 1.2% - 6.1%). Samples were stable for 5 days 38 
at 4˚C. The assay was linear within the assessed range. EDTA- and heparin-39 
anticoagulated blood can be used interchangeably for HbA1c measurement. The 40 
reference interval for HbA1c was 9 – 18.5mmol/mol. There was no apparent effect of 41 
age or breed on HbA1c. HbA1c ranged from 14 - 48 mmol/mol in dogs with DM. 42 
Conclusions: The assay provides a reliable method of canine HbA1c measurement 43 
with good analytical performance.  44 
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 48 
Abbreviations used 49 
ANOVA – analysis of variance 50 
CBC – complete blood count 51 
CI – confidence interval 52 
CV – coefficient of variance 53 
DM – diabetes mellitus 54 
EDTA – ethylenediaminetetraacetic acid 55 
HbA1c - hemoglobin A1c 56 
RCF – relative centrifugal force 57 




Glycosylated hemoglobin A1c (HbA1c) is formed when glucose binds to the n-62 
terminal valine of the β-subunit of hemoglobin A and makes up the largest fraction of 63 
the total glycosylated hemoglobin (HbA1)1. The total amount of HbA1c formed is 64 
dependent on erythrocyte lifespan, erythrocyte permeability to glucose and the 65 
average blood glucose concentration throughout that erythrocyte lifespan1. In people 66 
it is related to the average blood glucose concentration over the preceding 2-3 67 
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months, weighted towards the most recent 2-4 weeks2. Fructosamine – glycosylated 68 
plasma proteins - are currently a commonly used measure of longer term diabetic 69 
stability in the dog. Fructosamine are related to the average blood glucose 70 
concentration over the previous 1-2 weeks3, 4. However a number of factors other 71 
than plasma glucose concentration affect fructosamine concentration including 72 
hypoproteinemia, hyperlipidemia and azotemia4 Compared to fructosamine 73 
measurements, HbA1c is less affected by pathological conditions other than DM5.  74 
In people HbA1c has shown itself to be a highly specific and reliable biomarker for 75 
the long term control of both type 16 and type 2 DM7. HbA1c is also used 76 
prognostically with increasing values corresponding to increased risk of diabetic 77 
complications6. In dogs, there have been no studies looking at the relationship 78 
between fructosamine or HbA1c and outcome in DM. 79 
The measurement of HbA1c in dogs has been previously described. Several 80 
methods developed for human use have been evaluated for use in canine DM but 81 
none have been adopted into standard clinical practice. All published studies have 82 
however shown that canine diabetics have higher average ratios of glycosylated 83 
hemoglobin: total hemoglobin compared to non-diabetic controls3, 8-18.  84 
The first aim of this study was to determine the effect of increasing glucose 85 
concentrations on the production of canine HbA1c as measured by an 86 
immunoturbidimetric assay, the Siemens DCA™ Vantage (Siemens Healthcare plc. 87 
Surrey, UK), in canine erythrocyte preparations. The second aim was to validate this 88 
method and to establish a reference interval from a hospital population. The final aim 89 
was to assess the effect of breed pre-disposition and age on canine HbA1c within 90 
the reference population. 91 




Materials and Methods 93 
 94 
Animals and Samples 95 
Specimens obtained were all taken from dogs referred to the Small Animal Hospital, 96 
University of Glasgow. Ethical approval for this study was obtained from the School 97 
of Veterinary Medicine Ethics and Welfare committee, University of Glasgow.  98 
Hospital Population 99 
Surplus EDTA-anticoagulated and heparin-anticoagulated blood from samples that 100 
had been taken for diagnostic purposes by jugular venipuncture were used for the 101 
method validation aspect of the study. Screening for eligibility into the reference 102 
interval occurred between June and August 2015  with 60 samples meeting all 103 
criteria selected. The inclusion criteria were a record of a CBC  measured using a 104 
Cell-Dyn hematology analyzer (Abbott Laboratories, North Chicago, IL, USA) with 105 
WBC differential counts performed manually, and biochemistry analyses including a 106 
near normal plasma glucose concentration of 3-7mmol/L (54-126mg/dL) measured 107 
by the hexokinase G-6-PDH method in a fluoride oxalate-anticoagulated sample 108 
within 8 hours using an Olympus AU640 biochemistry analyzer (Olympus 109 
Corporation, Tokyo, Japan). As part of the biochemistry analyses cholesterol (by 110 
combined cholesterol esterase/oxidase method) and triglycerides (by combined 111 
lipolysis/ glycerol kinase/ glycerol phosphate oxidase method) were also measured 112 
on the Olympus AU640. Exclusion criteria were a diagnosis of DM or other endocrine 113 
disorders. Grossly hemolyzed and lipemic samples were excluded. Animals with a 114 
hemoglobin concentration <12 g/dL were excluded from the reference interval 115 
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population as anemia has been shown to have an effect on HbA1c in previous 116 
canine studies13 16. Animals with diseases unrelated to carbohydrate metabolism 117 
were not excluded. Information was collected on the animal’s age; breed, sex, co-118 
morbidities, current medication, blood glucose, and hemoglobin as well as any 119 
abnormalities found on hematology and biochemistry. To ensure a wide range of 120 
dogs were included in the reference interval population, dogs were prospectively 121 
recruited into 4 similarly sized sub-groups based on age and diabetic predisposition; 122 
young (=< 5 years old) non-predisposed, older (>5 years old) non-predisposed, 123 
young predisposed, and older predisposed. The diabetic predisposition was based 124 
on the list as shown in the supplementary information. 125 
Diabetic population 126 
Surplus heparin-anticoagulated and EDTA-anticoagulated blood samples, taken for 127 
monitoring purposes were also available for 10 diabetic dogs receiving insulin 128 
therapy. Diagnosis had been confirmed before sample collection on the basis of 129 
consistent clinical signs of polyuria, polydipsia and weight loss, concurrent 130 
hyperglycemia and glucosuria. Information was collected on age, breed, sex, co-131 
morbidities, medications, blood glucose, hemoglobin and any hematological and 132 
biochemical abnormalities as well as any serum fructosamine measurements 133 
performed using the Nitrotetrazolium blue reduction method on an Olympus AU640 134 
biochemistry analyser with ABX Horiba reagent kit (Horiba UK Ltd – Medical, 135 
Northampton, UK) as part of routine monitoring. 136 
Analysis of HbA1c 137 
Samples were analysed on a DCA™ Vantage using HbA1c reagent cartridges 138 
(Siemens DCA™ Systems Hemoglobin A1c reagent kit) which contain all reagents in 139 
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a single disposable cartridge that the sample is slotted into, effectively eliminating 140 
carry-over. The Siemens DCA™ Vantage uses murine anti-human HbA1c 141 
monoclonal antibodies specific to the last few amino acids on the N-terminal of the β-142 
chain19. Canine and human hemoglobin A are only 80% homologous, but the first 5 143 
residues of the N-terminal of the β-chain are identical16. HbA1c in the sample causes 144 
an inhibition of latex agglutination by binding competitively to the anti-HbA1c 145 
antibodies and decreasing absorbance at 531nm. Concurrently total hemoglobin is 146 
measured following the oxidation to methemoglobin, complexed with thiocyanate to 147 
form a colored compound which is measured spectrophotometrically at 531nm. 148 
HbA1c is expressed as a ratio of total hemoglobin in mmol/mol within 6 minutes. All 149 
reactions and calculations are carried out internally19. 150 
The samples were analysed according to the manufacturers’ instructions using 1μL 151 
of EDTA-anticoagulated blood. Before each batch run and when changing cartridge 152 
batch numbers a quality control run with one normal (range 24.6 - 48.6mmol/mol) 153 
and one abnormal (range 70 - 116.4mmol/mol) sample was performed using 154 
commercial control reagents (Siemens DCA™ systems).  155 
Incubation of canine hemoglobin with glucose 156 
EDTA-anticoagulated blood from 5 non-diabetic dogs with no hematological 157 
abnormalities was pooled. This sample was washed 3 times with phosphate buffered 158 
saline by centrifuging at a relative centrifugal force (RCF) of 1439 using a Beckman 159 
Coulter Allegra X-12R (Beckman Coulter, High Wycombe, UK) for 10 minutes. The 160 
washed erythrocytes were hemolyzed using a modified osmotic shock procedure20, 161 
then centrifuged at an RCF of 2249 for 15 minutes to sediment the cell debris. The 162 
hemolysate was divided into 5 aliquots of 600µL. The hemolysates were incubated at 163 
 Validation of a method for measuring canine HbA1c                        
8 
 
glucose concentrations of 0, 50, 100, 200 and 400 mmolL (equivalent to 900, 1800, 164 
3600 and 7200 mg/dL), stored at room temperature, and measured at days 0, 7, 11, 165 
and 17 after preparation. A separate pool of intact erythrocytes was washed in the 166 
same manner and half the sample was hemolyzed. Both hemolysates and intact 167 
erythrocytes were divided into 500µL aliquots and incubated at 4˚C in the same 168 
glucose concentrations as the room temperature hemolysates. Samples were 169 
measured at 0, 4, 7 and 14 days after preparation. 170 
Repeatability 171 
Samples were collected as described previously from both diabetic and non-diabetic 172 
animals to represent a large range of glucose concentrations. To evaluate the 173 
repeatability, the HbA1c of each sample (n=4) was measured 5 times in succession 174 
for each sample. To evaluate the inter-assay variability over the course of the study 175 
the results from the commercially available quality control materials were used.  176 
Storage stability was evaluated using 3 EDTA-anticoagulated samples kept at 4˚C. 177 
Samples were measured at baseline and then for 4 consecutive days, with the 178 
measurements at each time point compared to baseline. Stability of canine HbA1c at 179 
-20˚C was assessed by freezing 5 samples, measuring these after 4 and 8 weeks 180 
and comparing to baseline.  181 
Linearity 182 
Samples from 2 dogs were used. To achieve a range, one set of samples was from 183 
the reference interval and the other from the diabetic population. HbA1c was 184 
measured in the EDTA-anticoagulated samples  and then mixed in varying 185 
proportions (25:75, 50:50 and 75:25) to create 3 new intermediate expected values, 186 
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which were then compared to the measured HbA1c21. This was repeated with the 187 
heparin-anticoagulated samples to assess both linearity of the assay and the effect 188 
of different anti-coagulants to the measured HbA1c. 189 
Interference  190 
An initial investigation into the effect of lipemia on the assay was performed. EDTA-191 
anticoagulated samples were obtained as previously described. Samples from 7 192 
dogs with known total lipid concentrations, triglycerides from 0.68 – 25.58 mmol/L 193 
and cholesterol from 4.9 – 11.7 mmol/L were used. 4 of the samples came from 194 
diabetic dogs, 2 from non-diabetics who had been excluded from the reference 195 
interval due to gross hyperlipemia, and one control from the reference interval 196 
population. After assessing the baseline HbA1c, the samples were centrifuged 197 
(Beckman Coulter Allegra X-12R) at 2073 RCF at 6˚C for 12 minutes. The plasma 198 
was completely removed and an equal volume of 0.9%NaCl added. The packed red 199 
cells were re-suspended by mixing well and the samples were measured again.  200 
To assess the effect of complete hemolysis on HbA1c measurements, the starting 201 
time point results from the haemolyzed preparations used in the 4˚C glucose 202 
incubation experiments (described earlier) were compared to the results from the 203 
intact erythrocyte preparations (which were from the same pooled sample but had 204 
not undergone haemolysis).  205 
 206 
Statistical methods 207 
Statistical analysis was carried out in SPSS v22 (IBM) or Microsoft Excel 2010 for 208 
Windows with Reference Value Advisor Add-In 22. Statistical significance was set at 209 
p=0.05 for all analyses. 210 
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For the glucose incubation regression lines were fitted. The lines of measured 211 
HbA1c over time were fitted for each glucose concentration and compared against 212 
the control (0 mmolL glucose). The change in HbA1c from baseline was compared to 213 
glucose concentration for each time point using a linear regression and Pearson 214 
correlation. 215 
To evaluate linearity a least squares regression analysis was performed on expected 216 
against observed measurements. The difference between EDTA and heparin 217 
anticoagulant was evaluated by calculating the mean difference and performing a 218 
least squares regression analysis.  219 
The reference interval for the hospital population was determined using the non-220 
parametric method with bootstrapping to arrive at the 90% confidence interval for the 221 
whole population22. Both Tukey and Dixon-Reed tests were used to identify potential 222 
outliers. The reference interval comprises the central 95%, with 90% confidence 223 
intervals around the lower and upper limits. 224 
All factors assessed – HbA1c age, breed-predisposition, glucose, hemoglobin, sex - 225 
were summarised descriptively. Linear regression and correlations were performed 226 
to look at the relationship between HbA1c and glucose concentration, age and 227 
hemoglobin concentration. A regression model of HbA1c was fitted with age, 228 
haemoglobin concentration, sex, breed-predisposition and glucose concentration as 229 
co-factors.  230 
A Kruskal-Wallis ANOVA was used to assess the overall difference in HbA1c 231 
between the pre-specified reference interval groups. Subgroup analysis was 232 
performed within the reference population by comparing the median HbA1c in each 233 
 Validation of a method for measuring canine HbA1c                        
11 
 
subgroup to that of the median HbA1c of the other subgroups combined using a 234 
Mann-Whitney U test.  235 
For the diabetic population all factors assessed were summarised descriptively and 236 
compared to the reference interval population. Normally distributed factors were 237 
compared using an independent sample t-test and non-normally distributed factors 238 
were compared using a Mann-Whitney U test. 239 
Results 240 
HbA1c synthesis in vitro at room temperature using canine hemolysates increases 241 
with time and glucose concentration (Figure 1). Using a least squares regression to 242 
fit lines for each concentration over time, the concentrations were found to be 243 
significantly different from each other (p<0.001).  Additionally at each time point, the 244 
change in HbA1c from baseline against glucose concentration gave a linear 245 
relationship; day 7, Pearson correlation 0.968, R2 linear 0.937 (p=0.007); day 11, R2 246 
0.941 (p=0.006); day 17, R2 0.941(p=0.006). The increase in HbA1c over time was 247 
initially linear for all glucose concentrations, but  between days 11 and 17 the rate of 248 
change started to decrease. Further points were not measured. The aliquots kept at 249 
4˚C did not show any significant deviations from baseline after 14 days. 250 
The mean co-efficient of variation using canine samples measured 5 times in 251 
succession was 4.08% (range 1.16% - 6.10%) (Table 1) with a maximum difference 252 
of 2 mmol/mol between the highest and lowest measurement within any sample. 253 
One measurement of 57mmol/mol was excluded from the analysis of the canine 254 
diabetic sample due to operator error. 255 
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The inter-assay imprecision over the course of the study was 2.97% with the normal 256 
concentration quality control material (stabilised human hemoglobin) supplied by the 257 
manufacturer. The inter-assay imprecision with the high HbA1c commercial control 258 
had a larger CV of 8.81%. Bias was seen with an overestimation of the mean relative 259 
to the stated value (mean 93.5mmol/mol) (Table 1).   260 
There was a low variation due to storage over 5 days using the canine samples with 261 
a mean CV of 2.12% (Table 1). The maximum absolute change from baseline at any 262 
time point was 1 mmol/mol with a mean change from baseline after 5 days of -263 
0.3mmol/mol. After freezing for 4 weeks there was low variation compared to 264 
baseline with a maximum absolute change of 1 mmol/mol. After 8 weeks 4 samples 265 
showed a small change from baseline with the fifth showing a decrease of 7 266 
mmol/mol (-14%) from baseline. 267 
In the study of linearity, regression analysis of the heparin-anticoagulated and EDTA-268 
anticoagulated blood samples gave a linear relationship for both (Figure 2). R2 linear 269 
for EDTA was 0.982 and for heparin 0.957. For EDTA samples the y intercept was -270 
2.23mmol/mol (95% CI -4.539 to 0.077mmol/mol) and the slope was 1.031 (95% CI 271 
0.951 to 1.111). For the heparin samples the y intercept was -1.846mmol/mol (95% 272 
CI -5.5 to 1.8 mmol/mol) and the slope 1.046 (95% CI 0.918 – 1.174). For both lines 273 
the y intercept was not significantly different from 0, the slope was not different from 274 
1 and the lines were not significantly different from each other (p=0.92). The mean 275 
difference between the heparin and EDTA samples was -0.8mmol/mol. 276 
Regarding interference from hyperlipemia, the initial HbA1c measured ranged from 277 
11 to 34mmol/mol with a trend for increasing interference from lipids as the 278 
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triglyceride concentration increases (Table 2). The largest difference was 6mmol/mol 279 
(60% change from baseline for sample 5 and a 20.7% change for sample 7).   280 
The HbA1c values obtained from the hemolyzed pooled sample were higher, mean 281 
22mmol/mol, than the intact erythrocytes, mean 17.75mmol/mol, with no overlap 282 
between the two samples.  283 
The reference population comprised of 9 predisposed breeds and 18 non-284 
predisposed breeds. The most common predisposed breeds were Border collies 285 
(n=9), Bichon Frises (n=3), Cavalier King Charles Spaniels (n=3) and Yorkshire 286 
terriers (n=2). The most common non-predisposed breeds were Labradors (n=6), 287 
Crossbreeds (n=5), German Shepherd dogs (n=5), Golden Retrievers (n=4) and 288 
Cocker Spaniels (n=4). The reference interval was calculated from 60 animals. No 289 
outliers were excluded. The distribution of the reference values was not normal, 290 
Shapiro-Wilk p=0.03, showing evidence of a binomial distribution (Figure 3). Using 291 
the non-parametric method (n>40) a reference interval for HbA1c of 9 – 18.5 292 
mmol/mol was obtained with a lower limit 90% CI of 9 - 10.5mmol/mol and an upper 293 
limit 90% CI of 18 - 19mmol/mol. The mean value obtained was 14.3mmol/mol 294 
HbA1c (SD 2.5) with a total range of 9 - 19 mmol/mol observed for the reference 295 
population (Table 3).  296 
There was a weak positive correlation between HbA1c and plasma glucose 297 
concentration within the reference population, Spearman’s σ 0.332, r2=0.089. The 298 
correlations between age and HbA1c and between hemoglobin and HbA1c were not 299 
significant within the reference population. Within the regression model the overall 300 
adjusted r2 was low (0.146) and the only significant factor was glucose concentration 301 
(p=0.02) with an increase in HbA1c of 1.259 mmol/mol for every 1 mmol/L increase 302 
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in plasma glucose concentration. Both being neutered and being of a non-303 
predisposed breed decreased HbA1c in the model (estimate -0.8448, p=0.19 and -304 
1.002, p=0.12 respectively) but neither was statistically significant. Age, hemoglobin 305 
concentration and male vs female were all non-significant factors (p=0.09, p=0.23, 306 
p=0.68).   307 
Differences in age, sex and breed predisposition were observed between the groups 308 
(Table 3), but only the old non-predisposed group had a higher HbA1c (mean 309 
15.28mmol/mol) when compared to the rest of the reference interval (mean 310 
13.88mmol/mol) p=0.045.  There were no significant differences in HbA1c across the 311 
sub-groups using a Kruskal-Wallis ANOVA. There were also no significant 312 
differences when partitioning by age (p=0.442) or breed predisposition 313 
(p=0.213)(Figure 3).   314 
The DM group (n =10) was significantly older (p=0.005) and had a higher proportion 315 
of dogs of predisposed breeds(7/10) (p=0.047) compared to the reference interval 316 
population. As expected, the DM group had significantly higher glucose 317 
concentrations, mean 19.56mmolL vs. 4.9mmolL (p<0.001) (Table 3). The HbA1c, 318 
mean 36.5mmol/mol vs. 14.3mmol/mol (p<0.001), was also significantly higher 319 
(Figure 4). There were no differences in hemoglobin (p=0.454) and sex (p=0.442) 320 
between DM group and the reference population. Within the DM group there was no 321 
significant correlation between HbA1c and glucose concentration p=0.618 (n=9) or 322 
fructosamine p=0.827 (n=6).   323 
Discussion  324 
Using pooled erythrocytes from non-diabetic dogs it was demonstrated that 325 
incubation with glucose increased the proportion of HbA1c measured in vitro with 326 
 Validation of a method for measuring canine HbA1c                        
15 
 
increasing glucose concentration. From the known kinetics of the reaction1 2 and 327 
work using human erythrocyte preparations23, this increase was expected and thus 328 
suggests that the DCA™ Vantage is measuring the stable canine HbA1c fraction and 329 
that canine HbA1c can be used to quantify the long term glycemic control of a canine 330 
patient. Using human erythrocytes it was previously shown that HbA1c increases 331 
with increasing glucose concentrations at 4˚C23. However this was not replicated in 332 
our experiments, with values not deviating significantly from baseline after 14 days. 333 
The previous study used agar gel electrophoresis for detecting HbA1c, which does 334 
not differentiate between stable and labile fractions of HbA1c. However, the reaction 335 
of hemoglobin with glucose to form labile HbA1c occurs 11.9 times faster than to 336 
stable HbA1c2 and so increases were seen more quickly than in our study. The only 337 
previous study using canine erythrocyte preparations also looked at increases in 338 
labile HbA1c, incubating their preparations with a high glucose concentration for just 339 
6 hours and increasing glucose concentrations were not evaluated18. 340 
Intact erythrocytes were not used for the room temperature incubation as they are 341 
prone to extensive and variable hemolysis24. Using hemolysates controlled for this 342 
variable, but made the model less representative of in vivo conditions. We were 343 
however able to show that canine HbA1c increases in a dose dependent manner 344 
with increasing glucose concentration at room temperature. Despite 345 
supraphysiological glucose concentrations the reaction was slow. This is consistent 346 
with HbA1c as a measure of average glucose concentration over 2-3 months2. The 347 
results from this in vitro incubation are also consistent with previous findings that 348 
persistent hyperglycemia over 2 weeks is needed in order to see increases in HbA1c 349 
in vivo13.  350 
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Important components of a method validation study are imprecision and accuracy25. 351 
Imprecision in the DCA™ Vantage was low with a CV of 2.97% for the normal 352 
commercial quality control. This is comparable to CVs obtained by several 353 
independent studies validating the DCA™ Vantage for use in humans where < 3.1% 354 
was achieved26 27.  Slightly higher CVs were obtained during assessment of inter-355 
assay variation using canine samples, mainly due to the low samples showing 356 
proportionally much more variation with an overall range of 1mmol/mol compared to 357 
samples with a higher value. The overall imprecision is likely to be acceptable for 358 
veterinary use28. A much higher inter-assay variation (8.81%) was obtained from the 359 
high control. It is known that the DCA™ Vantage exhibits increased variance at 360 
readings above 64mmol/mol26. However as only a small number of diabetic animals 361 
were included in the study (with a maximum HbA1c of 48mmol/mol) it cannot be said 362 
whether this will impact veterinary use. Bias in the DCA™ Vantage could not be 363 
assessed for canine HbA1c measurements due to the absence of a canine reference 364 
method and the inaccessibility of previously validated methods. Comparison using 365 
high performance liquid chromatography set up for human HbA1c has been 366 
unsuccessful in previous canine studies3, 11, 18. With the human reference material 367 
the abnormal control showed considerable bias compared to the reported mean of 368 
the material, but this was marginal in the normal control. The effect of storage at 4˚C 369 
was minimal with a mean change from baseline of -0.33mmol/mol after 5 days. 370 
Different samples were used for the repeatability and storage assessments so 371 
variation cannot be compared directly, but the total variance from the storage 372 
assessment (CV 2.12%) was comparable to the inter-assay variation.  373 
The linearity study provided an indirect assessment of bias. The regression analysis 374 
confirmed that the line obtained experimentally was not significantly different from 375 
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y=x and thus there was no internal bias against expected values. The results 376 
obtained here are consistent with human data from independent studies19, 26. The 377 
high HbA1c used in assessing linearity was significantly lower than the highest 378 
reading obtained from any animal in this study (40mmol/mol vs. 48mmol/mol), so 379 
there is potential for unknown bias in the upper expected working ranges of the 380 
assay and means that we have not fully established the reportable range of this 381 
assay. However as validation of this assay for human samples has established a 382 
reportable range of < 143mmol/mol19 it is unlikely that any samples will exceed the 383 
reportable range when using the DCA™ Vantage for veterinary purposes. No 384 
significant difference was found between measurements obtained from blood 385 
anticoagulated with EDTA or heparin before analysis. The mean difference of -386 
0.8mmol/mol and lack of significant differences between the regression lines, 387 
suggests that these anticoagulants can be used interchangeably in the measurement 388 
of canine HbA1c.  389 
In these preliminary investigations, hemolysis and hyperlipemia appear to interfere 390 
with the HbA1c measurement obtained by the DCA™ Vantage. The preliminary 391 
investigations were designed to test whether there was interference when using 392 
patient samples with the concentration range of interferent expected with clinical use, 393 
to determine where further investigation is warranted29. The manufacturers report 394 
that, for human samples, there is a bias of -1.81% at triglyceride concentrations of 395 
15.2mmol/L for HbA1c measurements in the 42-48mmol/mol range, but no data on 396 
the magnitude of interference beyond this is available. As dogs may have triglyceride 397 
concentrations in excess of 15.2mmol/L30, it was important to determine whether 398 
there may be an effect of hyperlipidemia on the HbA1c as measured by the device. 399 
Samples with a total lipid concentration of 25mmol/L and above showed increases 400 
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from baseline in measured HbA1c concentration after lipid removal that were larger 401 
than the inherent imprecision within the method. It gives an early indication that 402 
measured HbA1c may be artificially reduced in samples with gross hyperlipidemia 403 
and this should be investigated further using established guidelines21. Similarly, 404 
hemolyzing a pooled sample significantly increased the HbA1c reading obtained 405 
compared to baseline. This was surprising as the DCA™ Vantage hemolyzes the 406 
sample internally before analysis. So far only 100% hemolysis has been looked at 407 
and further investigation will be necessary to determine the maximum acceptable 408 
sample hemolysis. The other main interferent which is often looked at in validation 409 
studies is bilirubin, however unfortunately no sufficiently icteric samples were 410 
obtained during the course of the study.  411 
The reference interval was 9 – 18.5mmol/mol for canine HbA1c in a hospital 412 
population. With an assay specific for canine HbA1c we would expect a lower 413 
reference interval compared to the human reference interval due to the decreased 414 
glucose permeability of canine erythrocytes compared to human erythrocytes1. The 415 
human reference interval is 20 – 42mmol/mol. As there is no canine reference 416 
method, our results cannot be readily compared to previous studies. When 417 
comparing our results to those obtained with previously evaluated methods for 418 
canine HbA1c still available for human use1617, our reference interval was 419 
significantly lower. As a point of note, one of the previous studies35 determined 420 
health based on the absence of clinical signs and did not specifically exclude anemic 421 
dogs. Anemic dogs were excluded in our study as there is evidence of an effect on 422 
canine HbA1c independent of glucose concentration13 16 31.  423 
The hospital population may not mirror the true healthy population, despite evidence 424 
that most pathological processes do not affect HbA1c13. A previous study did not 425 
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show any differences between the reference interval obtained from a hospital sample 426 
compared to healthy animals, but their healthy population consisted of 18 juvenile 427 
colony beagles3. The ethical issues involved with collecting samples from healthy 428 
animals for research purposes preclude the use of healthy reference animals32 429 
(regulated under the Animals Scientific Procedures Act 1986). The reference interval 430 
is however relevant to dogs presented to a small animal hospital. Using this 431 
reference interval in other situations may not be appropriate. Sample size is another 432 
potential limitation in this study in that it reduced the power of the study to detect 433 
small differences between sub-groups. Despite a previous study with a larger sample 434 
size observing normality11, the distribution of reference values of HbA1c in our study 435 
was not normal (Figure 3). The reason for this distribution is not clear. The study was 436 
large enough, however, to establish a reference interval in line with American 437 
Society of Veterinary Clinical Pathology recommendations33 with good confidence in 438 
the range as shown by the tight 90% confidence intervals.  439 
Information was specifically collected with a view to partitioning the reference 440 
population into subgroups.  When performing subgroup analysis, the HbA1c was 441 
found to be significantly higher in the old non-predisposed group when compared to 442 
the rest of the reference interval, but a Kruskal-Wallis ANOVA identified no 443 
significant differences between the groups. There was no difference when 444 
partitioning solely by age (Figure 3), which is consistent with previous studies3, 14. To 445 
our knowledge breed predisposition has not been previously examined in 446 
conjunction with HbA1c. There was no significant effect of breed predisposition on 447 
HbA1c. However it is acknowledged that, as we only looked at predisposed 448 
compared to non-predisposed breeds, our categorization may have reduced the 449 
ability to detect a true difference in HbA1c in specific breeds or in the small sub-450 
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group of non-predisposed breeds that might be considered ‘protected’ against 451 
diabetes mellitus. . Predisposed breeds are not likely to have a higher HbA1c as the 452 
clinical course of canine DM is comparable to human type 1 disease34 35. However 453 
as little is known about breed differences in erythrocyte permeability, but at least one 454 
breed associated difference has been identified36 , it follows that some breeds may 455 
have higher (or lower) HbA1c concentrations.  456 
In order for canine HbA1c to be adopted as an effective biomarker for long term 457 
diabetic control, an independent objective assessment of diabetic control needs to 458 
be developed. It will then be possible to assess the relative values of HbA1c and 459 
fructosamine as markers of long term diabetic control.   460 
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Tables  576 
 577 
 
Table 1: Co-efficients of variance and measured HbA1c (mmol/mol) for control 578 
materials and canine samples and variation during storage over 5 days 579 






mean3 Bias4  
       Repeatability canine 1 8 - 9 8.2 6.10% - - 
 
canine 2 13 - 15 14.2 5.75% - - 
 
canine 3  17 - 18 17.4 3.32% - - 
 
canine 4 43 - 44 43.3 1.16% - - 
 
mean canine samples     4.08% 
  
       Inter-assay1  normal control (n=9) 36 - 39 36.9 2.97% 36.6 -0.49% 
 
abnormal control (n=9) 90 - 116 104.7 8.81% 93.5 10.29% 
       Storage2 canine 5 17 - 18 17.6 3.11% - -
 
canine 6 39 - 40 39.4 1.39% - - 
 
canine 7 48 - 50 48.4 1.85% - - 
 mean canine samples     2.12%     
1Long term inter-assay variation using commercially available control materials (stabilised human 580 
hemoglobin). 2Storage over 5 days at 4˚C. 3The mean HbA1c of the commercially available material 581 
as reported by the manufacturer. 4The bias in the mean of the measured HbA1c against the reported 582 
mean value. 583 
 584 




Table 2: Interference in the HbA1c assay using patient samples with increasing 586 
hyperlipidemia 587 
 588 
                
  
total lipids2 TG  (RI <0.6) cholesterol (RI <7) HbA1c pre3 HbA1c post4 Difference5 
n1 Diabetic (mmolL) (mmolL) (mmolL) (mmol/mol) (mmol/mol) (mmol/mol) 
1 
 
5.62 0.68 4.94 15 15 0 
2 Yes 15.35 7.05 8.30 34 34 0 
3 Yes 19.55 9.26 10.29 13 13 0 
4 
 
21.59 11.64 9.95 13 14 + 1 
5 Yes 25.28 14.88 10.40 10 16 + 6 
6 
 
31.7 4.7 27.00 11 14 + 3 
7 Yes 36.65 25.58 11.07 29 35 + 6 
TG: Triglycerides, RI: Reference Interval. 1Sample number. 2 Total measured lipids is defined as the sum of 589 
triglycerides and cholesterol. 3HbA1c as measured at baseline. 4HbA1c after removal of interferent containing 590 






Table 3: Characteristics for the reference interval subgroups and combined 597 
reference interval 598 
 599 




















n=20 n=18 n=9 n=13 n=60 n=10 
Age Mean (SD) 3.25 (1.29) 9.28 (2.45) 2.11 (1.27) 8.85(1.63) 6.1 (3.60) 10.10 (3.96) 
Median 4 9 2 9 5 10.5 
Range 1 - 5 6 - 14 1 - 4 6 - 11 1 - 14  1 - 14 
Sex   
    
  
        male entire n(%) 5 (25%) 8 (44.4%) 4 (44.4%) 1 (7.7%) 18 (30%) 1(10%)
male neut  n(%) 1 (5%) 4 (22.2%) 1 (11.1%) 4 (30.8%) 10 (16.7%) 5 (50%) 
female entire n(%) 5 (25%) 2 (11.1%) 0 (0%) 3 (23.1%) 10 (16.7%) 1 (10%) 
female neut n(%) 9 (45%) 4 (22.2%) 4 (44.4%) 5 (38.5%) 22 (36.7%) 3 (30%) 
Breed predisposition 
    
  
 Yes n(%) 
    
22 (36.7%) 7 (70%)
no  n(%) 
    
38 (63.3%) 3 (30%) 
Blood glucose (mmolL) 
   
  
 Mean (SD) 4.83 (0.469) 4.96 (0.544) 5.18 (0.954) 4.94 (0.549) 4.9 (0.596) 19.56 (10.6)
Median  4.9 5 5.3 4.9 4.9 19.3 
Range 3.8 - 5.9 3.7 - 5.8 3.6 - 6.8 4.1 - 5.9 3.6 - 6.8 3.9 - 35.1 
Hemoglobin (g/dL) 
    
  
 Mean (SD) 15.98 (2.32) 15.51 (1.80) 15.77 (1.71) 15.78 (3.25) 15.8 (2.29) 15.09 (1.43)
Median  15.8 15.15 16.1 15.5 15.7 15.1 
Range 13 - 20.3 12.6 - 19.2 12.6 - 17.9 11 - 23.2 11 - 23.2 13.4 - 17.5 
HbA1c (mmol/mol) 
    
  
 Mean (SD) 14.1 (2.5) 15.28 (1.97) 13.89 (2.32) 13.62 (3.20) 14.3 (2.5) 36.5 (9.94)
Median 13.5 15.5 13 13 14 39 
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 Range 10 - 18 11 - 18 11 - 18 9 - 19 9 - 19 14 - 48 
 601 
Figure Legends 602 
 603 
Figure 1: Change in HbA1c in hemolysates incubated with increasing 604 
concentrations of glucose at room temperature. ♦ 400mM glucose, ▼ 200mM 605 
glucose, ▲ 100mM glucose, ■50mM glucose, ●0mM glucose.  606 
 607 
  608 
Figure 2: Scatter plot of expected HbA1c values against observed HbA1c 609 
measurements in mmol/mol using 2 baseline samples and 3 intermediate 610 
mixes(25:75, 50:50, 75:25) using EDTA (squares) and heparin-anticoagulated 611 
blood (triangles) blood. Straight lines are regression lines; dotted line is y=x. 612 
 613 
Figure 3: Histogram of all reference values (n=60) partitioned by age (left 614 
panel) and breed disposition (right panel). 615 
 616 
Figure 4: Boxplot of HbA1c values of the reference group compared to the 617 
diabetic group. The box represents the interquartile range and is bisected by a 618 
line representing the median. The lines represent the main body of data with 619 
open circles representing outlying points. 620 
